-
公开(公告)号：US08778900B2
公开(公告)日：2014-07-15
申请号：US11042768
申请日：2005-01-24
申请人： Brett P. Monia , Sanjay Bhanot , Kenneth W. Dobie , Ravi Jain
发明人： Brett P. Monia , Sanjay Bhanot , Kenneth W. Dobie , Ravi Jain
CPC分类号： C07H21/04 , C07H21/02 , C12N15/113 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , C12Q1/6883 , C12Q2600/136 , C12Q2600/158 , C12N2310/3525
摘要： Compounds, compositions and methods are provided for modulating the expression of eIF4E-BP1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding eIF4E-BP1. Methods of using these compounds for modulation of eIF4E-BP1 expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E-BP1 are provided.
摘要翻译： 提供化合物，组合物和方法用于调节eIF4E-BP1的表达。 组合物包含靶向编码eIF4E-BP1的核酸的寡核苷酸。 提供了使用这些化合物调节eIF4E-BP1表达和用于诊断和治疗与eIF4E-BP1表达相关的疾病和病症的方法。
-
62.发明授权公开(公告)号：US08455456B2
公开(公告)日：2013-06-04
申请号：US13177457
申请日：2011-07-06
申请人： Xing-Xian Yu , Sanjay Bhanot , Brett P. Monia
发明人： Xing-Xian Yu , Sanjay Bhanot , Brett P. Monia
CPC分类号： C12N15/1137 , C12N2310/11 , C12Y203/0102
摘要： Disclosed herein are compounds, compositions and methods for modulating DGAT-1 activity. Preferably, the expression of DGAT-1 from a nucleic acid is inhibited. Methods are provided for treating, ameliorating or treating liver fibrosis, either directly or by treating an underlying etiological factor. Preferably, the treatment, amelioration or prevention comprises administering a DGAT-1 activity modulator.
摘要翻译： 本文公开了用于调节DGAT-1活性的化合物，组合物和方法。 优选地，来自核酸的DGAT-1的表达被抑制。 提供了直接治疗或改善肝纤维化或通过治疗潜在病因的方法。 优选地，治疗，改善或预防包括施用DGAT-1活性调节剂。
-
公开(公告)号：US08389488B2
公开(公告)日：2013-03-05
申请号：US12740974
申请日：2008-11-05
申请人： Brett P. Monia , Andrew M. Siwkowski , Hong Zhang
发明人： Brett P. Monia , Andrew M. Siwkowski , Hong Zhang
CPC分类号： C12N15/11 , C12N15/111 , C12N15/113 , C12N2310/11 , C12N2310/321 , C12N2310/341 , C12N2320/50 , C12N2310/3525
摘要： The present invention relates to antisense antidote compounds and uses thereof. Such antidote compounds reduce the magnitude and/or duration of the antisense activity of an antisense compound.
摘要翻译： 本发明涉及反义解毒剂化合物及其用途。 这样的解毒剂化合物降低了反义化合物的反义活性的大小和/或持续时间。
-
公开(公告)号：US08258289B2
公开(公告)日：2012-09-04
申请号：US12748281
申请日：2010-03-26
申请人： Sanjay Bhanot , Kenneth W. Dobie , Xing-Xian Yu , Brett P. Monia
发明人： Sanjay Bhanot , Kenneth W. Dobie , Xing-Xian Yu , Brett P. Monia
IPC分类号： C07H21/04
CPC分类号： C12N15/1137 , C07H21/02 , C12N2310/11 , C12N2310/14
摘要： Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 2. Methods of using these compounds for modulation of diacylglycerol acyltransferase 2 expression and for diagnosis and treatment of diseases and conditions associated with expression of diacylglycerol acyltransferase 2 are provided.
摘要翻译： 提供化合物，组合物和方法用于调节二酰基甘油酰基转移酶2的表达。该组合物包含靶向编码二酰基甘油酰基转移酶的核酸的寡核苷酸2.使用这些化合物调节二酰基甘油酰基转移酶2表达并用于诊断和治疗疾病的方法 提供了与二酰基甘油酰基转移酶2的表达相关的病症。
-
公开(公告)号：US20120149755A1
公开(公告)日：2012-06-14
申请号：US13185406
申请日：2011-07-18
申请人： Brett P. Monia
发明人： Brett P. Monia
IPC分类号： A61K31/7088 , A61P35/04
CPC分类号： C12N15/1137 , A61K38/00 , C07H21/00 , C12N15/1135 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , C12N2310/3517 , C12N2310/3525 , C12N2310/3527 , C12N2310/3521
摘要： Oligonucleotides are provided which are targeted to nucleic acids encoding human raf and capable of inhibiting raf expression. The oligonucleotides may have chemical modifications at one or more positions and may be chimeric oligonucleotides. Methods of inhibiting the expression of human raf using oligonucleotides of the invention are also provided. The present invention further comprises methods of inhibiting hyperproliferation of cells and methods of treating or preventing conditions, including hyperproliferative conditions, associated with raf expression.
摘要翻译： 提供寡核苷酸，其靶向编码人raf的核酸并能够抑制raf表达。 寡核苷酸可以在一个或多个位置具有化学修饰，并且可以是嵌合寡核苷酸。 还提供了使用本发明的寡核苷酸抑制人raf表达的方法。 本发明还包括抑制细胞过度增殖的方法以及治疗或预防与raf表达相关的病症（包括过度增殖病症）的方法。
-
公开(公告)号：US20110207797A1
公开(公告)日：2011-08-25
申请号：US13008704
申请日：2011-01-18
IPC分类号： A61K31/7088 , A61P9/00 , A61P3/00 , A61P3/10 , A61P3/04 , A61P3/06 , A61P1/16 , A61P9/10 , A61P9/12 , A61P7/02
CPC分类号： C12N15/111 , C12N2310/315 , C12N2310/321 , C12N2310/341 , C12N2310/346 , C12N2320/50 , C12N2310/3525
摘要： Described herein are gap-widened antisense oligonucleotides having improved therapeutic index as compared to 5-10-5 MOE gapmer antisense oligonucleotides of the same sequence. Also described are methods of reducing a target RNA in an animal using the gap-widened antisense oligonucleotides of the present invention. Further, are methods for selecting a gap-widened antisense oligonucleotides.
摘要翻译： 与相同序列的5-10-5个MOE gapmer反义寡核苷酸相比，本文描述了具有改善的治疗指数的间隙扩大的反义寡核苷酸。 还描述了使用本发明的间隙加宽的反义寡核苷酸还原动物中的靶RNA的方法。 此外，是选择间隙扩大的反义寡核苷酸的方法。
-
67.发明授权公开(公告)号：US07981868B2
公开(公告)日：2011-07-19
申请号：US10568488
申请日：2004-08-12
CPC分类号： C12N15/1137 , A61K31/7052 , A61K38/00 , C12N2310/11 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , C12Y207/11024 , Y02P20/582 , C12N2310/3525
摘要： Compositions and methods for the treatment and diagnosis of diseases or conditions amenable to treatment through modulation of expression of a gene encoding a p38 mitogen-activated protein kinase (p38 MAPK) are provided. Methods for decreasing airway hyperresponsiveness or airway inflammation in an animal are also provided.
摘要翻译： 提供了用于治疗和诊断适于通过调节编码p38丝裂原活化蛋白激酶（p38MAPK）的基因的表达进行治疗的疾病或病症的组合物和方法。 还提供了降低动物气道高反应性或气道炎症的方法。
-
公开(公告)号：US20110059895A1
公开(公告)日：2011-03-10
申请号：US12742076
申请日：2008-11-05
申请人： Susan M. Freier , Brett P. Monia , Hong Zhang , Chenguang Zhao
发明人： Susan M. Freier , Brett P. Monia , Hong Zhang , Chenguang Zhao
CPC分类号： C12N15/113 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/3231 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , C12N2310/3525
摘要： Disclosed herein are antisense compounds and methods for decreasing Factor 9 and increasing clotting time in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 9 include thrombosis, embolism, thromoboembolism such as deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke.
摘要翻译： 本文公开了用于减少因子9并增加有需要的个体中的凝血时间的反义化合物和方法。 通过施用靶向因子9的反义化合物可以改善的疾病状况的实例包括血栓形成，栓塞，血栓栓塞如深静脉血栓形成，肺栓塞，心肌梗死和中风。
-
公开(公告)号：US20090306179A1
公开(公告)日：2009-12-10
申请号：US12299609
申请日：2007-05-07
申请人： Sanjay Bhanot , Richard S. Geary , Robert McKay , Brett P. Monia , Punit P. Seth , Andrew M. Siwkowski , Eric E. Swayze , Edward Wancewicz
发明人： Sanjay Bhanot , Richard S. Geary , Robert McKay , Brett P. Monia , Punit P. Seth , Andrew M. Siwkowski , Eric E. Swayze , Edward Wancewicz
IPC分类号： A61K31/7052 , C07H21/00 , C12N5/00 , A61P3/00
CPC分类号： C12N15/113 , C12N15/1137 , C12N2310/11 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/341 , C12N2310/3515 , C12Y203/0102 , C12N2310/3521
摘要： The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
摘要翻译： 本公开描述了短反义化合物，包括长度为化学修饰的高亲和力单体8-16单体的这类化合物。 某些这样的短反义化合物可用于在增加的效力和改善的治疗指数的细胞，组织和动物中还原靶核酸和/或蛋白质。 因此，本文提供了包含用于在体内降低靶RNA的高亲和力核苷酸修饰的短反义化合物。 这样的短反义化合物在比以前描述的反义化合物低的剂量下是有效的，允许降低毒性和治疗成本。 此外，所述短反义化合物具有更大的口服给药潜力。
-
公开(公告)号：US20090292006A1
公开(公告)日：2009-11-26
申请号：US12299605
申请日：2007-05-07
申请人： Sanjay Bhanot , Richard S. Geary , Robert McKay , Brett P. Monia , Punit P. Seth , Andrew M. Siwkowski , Eric E. Swayze , Edward Wancewicz
发明人： Sanjay Bhanot , Richard S. Geary , Robert McKay , Brett P. Monia , Punit P. Seth , Andrew M. Siwkowski , Eric E. Swayze , Edward Wancewicz
CPC分类号： C12N15/113 , C12N15/1137 , C12N2310/11 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/341 , C12N2310/3515 , C12Y203/0102 , C12N2310/3521
摘要： The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
摘要翻译： 本公开描述了短反义化合物，包括长度为化学修饰的高亲和力单体8-16单体的这类化合物。 某些这样的短反义化合物可用于在增加的效力和改善的治疗指数的细胞，组织和动物中还原靶核酸和/或蛋白质。 因此，本文提供了包含用于在体内降低靶RNA的高亲和力核苷酸修饰的短反义化合物。 这样的短反义化合物在比以前描述的反义化合物低的剂量下是有效的，允许降低毒性和治疗成本。 此外，所述短反义化合物具有更大的口服给药潜力。
-
-
-
-
-
-
-
-
-
搜索结果
170 条记录 (耗时 0.069 秒)
